FOR IMMEDIATE RELEASE - July 28, 2017 - WASHINGTON, D.C. - Today, Commissioner of the U.S. Food & Drug Administration, Dr. Scott Gottlieb, announced a new comprehensive plan for the approach the agency will take to the regulation of tobacco products, placing an emphasis on a science-based method, that notes a "continuum of risk" that recognizes the differences in tobacco products.
Earlier today the United States Senate confirmed Dr. Scott Gottlieb as the next Commissioner of the Food & Drug Administration (FDA). IPCPR applauds the Senate’s decision to put thoughtful and experienced leadership at the head of an organization as critical as the FDA. Dr. Gottlieb’s confirmation puts a reform minded physician with experience in both the public and private sectors in charge of a regulatory body that has too often failed in its mission to protect the public health without needlessly hampering commerce in this country. The small business retailers and professional tobacconists that make up IPCPR are counting on the leadership of Dr. Gottlieb and the actions of his FDA to address and correct the onerous and catastrophic elements of last year’s Deeming Rule.